Swk Holdings Corp SWKH
We take great care to ensure that the data presented and summarized in this overview for SWK Holdings Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SWKH
View all-
Carlson Capital L P Dallas, TX9.09MShares$152 Million95.11% of portfolio
-
M3 F, Inc. Salt Lake City, UT781KShares$13 Million4.16% of portfolio
-
Cannell Capital LLC Alta, WY382KShares$6.38 Million1.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA268KShares$4.47 Million0.0% of portfolio
-
Black Rock Inc. New York, NY139KShares$2.33 Million0.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX109KShares$1.82 Million0.04% of portfolio
-
Geode Capital Management, LLC Boston, MA75.3KShares$1.26 Million0.0% of portfolio
-
Empowered Funds, LLC51.9KShares$866,3960.01% of portfolio
-
State Street Corp Boston, MA49.9KShares$833,4460.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX43.2KShares$720,6380.0% of portfolio
Latest Institutional Activity in SWKH
Top Purchases
Top Sells
About SWKH
SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. In addition, the company engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Its product pipeline includes Ovarest, an oral leuprolide tablet to treat endocrine disease. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.
Insider Transactions at SWKH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 23
2024
|
Carlson Capital L P |
SELL
Other acquisition or disposition
|
Indirect |
600,678
-100.0%
|
-
|
|
Jul 03
2024
|
Adam Rice Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,072
+50.0%
|
-
|
|
Jul 01
2024
|
Marcus Edward Pennington Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,051
+4.52%
|
$16,816
$16.89 P/Share
|
|
Jun 27
2024
|
Marcus Edward Pennington Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,253
+13.32%
|
$52,048
$16.91 P/Share
|
|
Jun 27
2024
|
Jerry Albright Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,253
+31.81%
|
$52,048
$16.91 P/Share
|
|
Jun 27
2024
|
Robert K. Hatcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,253
+20.26%
|
$52,048
$16.91 P/Share
|
|
Jun 27
2024
|
Laurie L. Dotter Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,253
+20.1%
|
$52,048
$16.91 P/Share
|
|
Apr 01
2024
|
Laurie L. Dotter Director |
BUY
Grant, award, or other acquisition
|
Direct |
815
+7.77%
|
$13,040
$16.88 P/Share
|
|
Apr 01
2024
|
Marcus Edward Pennington Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,866
+5.07%
|
$29,856
$16.88 P/Share
|
|
Apr 01
2024
|
Robert K. Hatcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
815
+7.86%
|
$13,040
$16.88 P/Share
|
|
Apr 01
2024
|
Jerry Albright Director |
BUY
Grant, award, or other acquisition
|
Direct |
815
+17.97%
|
$13,040
$16.88 P/Share
|
|
Mar 01
2024
|
Joe David Staggs Jr PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
35,881
+31.19%
|
-
|
|
Jan 02
2024
|
Marcus Edward Pennington Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,532
+4.66%
|
$26,044
$17.95 P/Share
|
|
Jan 02
2024
|
Robert K. Hatcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
766
+8.06%
|
$13,022
$17.95 P/Share
|
|
Jan 02
2024
|
Jerry Albright Director |
BUY
Grant, award, or other acquisition
|
Direct |
766
+20.86%
|
$13,022
$17.95 P/Share
|
|
Jan 02
2024
|
Laurie L. Dotter Director |
BUY
Grant, award, or other acquisition
|
Direct |
766
+7.95%
|
$13,022
$17.95 P/Share
|
|
Oct 02
2023
|
Jerry Albright Director |
BUY
Grant, award, or other acquisition
|
Direct |
868
+28.86%
|
$13,020
$15.85 P/Share
|
|
Oct 02
2023
|
Laurie L. Dotter Director |
BUY
Grant, award, or other acquisition
|
Direct |
868
+9.68%
|
$13,020
$15.85 P/Share
|
|
Oct 02
2023
|
Robert K. Hatcher Director |
BUY
Grant, award, or other acquisition
|
Direct |
868
+9.82%
|
$13,020
$15.85 P/Share
|
|
Oct 02
2023
|
Marcus Edward Pennington Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,988
+6.61%
|
$29,820
$15.85 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 64.2K shares |
|---|
| Other acquisition or disposition | 601K shares |
|---|